Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

Biotechnology

Healthcare
$2.29 +0.67%

+$0.02 today

Market cap
$165.63M
Beta
0.35
P/E (TTM)
-1.3
EPS (TTM)
-$1.79
52W Low $1.10High $3.60

Volume 0.81M

Average 0.40M

ABOS Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Acumen Pharmaceuticals, Inc.NASDAQ: ABOS

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 63.22M shares rose 4.5% year over year, ahead of the +1.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 4.4% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4.5% holds above the trailing-twelve-month pace of +1.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
63.22M+4.4% QoQ
Last fiscal yearDec 2025
60.56M+0.9% YoY
LTMMar 2026
61.23M+1.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.5%——
1 year+0.9%——
3-year CAGR+14.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
60.56M USD
Year-over-year change
+0.9%
4-year CAGR
+12.2%

Weighted Avg Shares (Diluted) vs competitors

How ABOS compares with its peers on the latest reported figures

  • ABOS's LTM Mar 2026 weighted avg shares (diluted) of 61.23M shares is the 5th highest of the 10 companies compared; the peer median is 57.24M shares.
  • Its year-over-year change of +1.8% is the 8th highest of 10, against a peer median of +10.4%.
  • Over three fiscal years its annual growth of +14.3% compares with a peer median of +16.2%.
ABOS Competitors Peer median
Weighted Avg Shares (Diluted) for ABOS and competitors
Company Period LTM YoY 3-year CAGR
IRDOpus Genetics, Inc.LTM Mar 2026406.29M +1283.9%+211.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026312.72M +1040.7%+186.8%
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
ALECAlector, Inc.LTM Mar 2026104.14M +6.5%+7.7%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 202661.23M +1.8%+14.3%
SPROSpero Therapeutics, Inc.LTM Mar 202657.24M +5.3%+16.2%
SEERSeer, Inc.LTM Mar 202656.96M -7.5%-2.7%
AGENAgenus Inc.LTM Mar 202633.65M +50.2%+28.3%
ACTUActuate Therapeutics IncLTM Mar 202621.96M +12.5%+11.8%
MCRBSeres Therapeutics, Inc.LTM Mar 20268.99M +10.4%+18.0%
Peer median (excluding ABOS) 57.24M+10.4%+16.2%

Competitors are the stored peer set for ABOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue12.31M0000
Gross Profit(12.31M)0000
Gross Margin—————
Research & Development12.31M32.36M42.32M93.8M104.89M
Selling, General & Admin7.28M12.88M18.82M20.22M18.95M
Operating Expenses7.28M45.24M61.14M114.02M123.83M
Depreciation & Amortization4K169K184K178K184K
EBITDA(100.6M)(42.69M)(51.61M)(98.08M)(116.93M)
EBITDA Margin—————
Operating Income(19.58M)(45.24M)(61.14M)(114.02M)(123.83M)
Operating Margin—————
Interest Income84K2.39M10.79M14.32M7.45M
Interest Expense00581K4.07M4.22M
Other Income / Expenses(81.02M)2.38M8.77M11.69M2.5M
Income Before Tax(100.61M)(42.86M)(52.37M)(102.33M)(121.34M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(100.61M)(42.86M)(52.37M)(102.33M)(121.34M)
Net Margin—————
EPS (Basic)(2.63)(1.06)(1.08)(1.71)(2.00)
EPS (Diluted)(2.63)(1.06)(1.08)(1.71)(2.00)
Weighted Avg Shares38.27M40.6M48.49M60.01M60.56M
Weighted Avg Shares (Diluted)38.27M40.6M48.61M60.01M60.56M

Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

Intrinsic Alpha fair value

Locked

Current Price

$2.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.